Effect of a new injectable male contraceptive on the seminal plasma amino acids studied by proton NMR spectroscopy

被引:17
作者
Chaudhury, K
Sharma, U
Jagannathan, NR
Guha, SK [1 ]
机构
[1] Indian Inst Technol, Ctr Biomed Engn, New Delhi, India
[2] All India Inst Med Sci, Dept NMR, New Delhi, India
关键词
male contraceptive; RISUG (TM); seminal plasma; azoospermia; amino acids; proton NMR;
D O I
10.1016/S0010-7824(02)00343-8
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Effect of RISUG(TM), a newly developed male contraceptive, on various amino acids of seminal plasma ejaculates was studied by proton magnetic resonance spectroscopy at 400 MHz. Levels of amino acids were compared with the seminal plasma of obstructive azoospermia and controls. Glutamic acid, glutamine, and arginine were found to be high in concentration in human seminal plasma. The concentration of aromatic amino acids such as tyrosine, histidine, and phenylalanine in RISUG-injected subjects showed no significant difference compared to controls (p > 0.1); however, there was a statistically significant decrease in the concentration of these amino acids in obstructive azoospermia. The concentration of some prominent amino acids that showed overlapping resonances, such as isoleucine+leucine+valine (p < 0.01), alanine+isoleucine+lysine (p < 0.01), arginine+lysine+leucine (p < 0.01), and glutamic acid+glutarnine (p < 0.01), showed a statistically significant decrease in RISUG-injected subjects compared to controls. Overlap of these amino acid resonances were noticed even at 600 MHz. In general, the total amino acids concentration in RISUG-injected subjects was found to be higher than in azoospermic subjects, confirming the occurrence of 'partial' obstructive azoospermia in subjects injected with this contraceptive. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:199 / 204
页数:6
相关论文
共 29 条
[1]
Aydin S., 1995, International Urology and Nephrology, V27, P199, DOI 10.1007/BF02551320
[2]
AMINO-ACID COMPOSITION OF SEMEN AND SECRETIONS OF MALE REPRODUCTIVE-TRACT [J].
BROWNWOODMAN, PD ;
WHITE, IG .
AUSTRALIAN JOURNAL OF BIOLOGICAL SCIENCES, 1974, 27 (04) :415-422
[3]
FROLICH JU, 1980, ANDROLOGIA, V12, P162
[4]
Guha S K, 1999, Asian J Androl, V1, P131
[5]
Phase II clinical trial of a vas deferens injectable contraceptive for the male [J].
Guha, SK ;
Singh, G ;
Ansari, S ;
Kumar, S ;
Srivastava, A ;
Koul, V ;
Das, HC ;
Malhotra, RL ;
Das, SK .
CONTRACEPTION, 1997, 56 (04) :245-250
[6]
PHASE-I CLINICAL-TRIAL OF AN INJECTABLE CONTRACEPTIVE FOR THE MALE [J].
GUHA, SK ;
SINGH, G ;
ANAND, S ;
ANSARI, S ;
KUMAR, S ;
KOUL, V .
CONTRACEPTION, 1993, 48 (04) :367-375
[7]
Two-year clinical efficacy trial with dose variations of a vas deferens injectable contraceptive for the male [J].
Guha, SK ;
Singh, G ;
Srivastava, A ;
Das, HC ;
Bhardwaj, JC ;
Mathur, V ;
Koul, V ;
Malhotra, RL ;
Das, SK .
CONTRACEPTION, 1998, 58 (03) :165-174
[8]
TIME-CONTROLLED INJECTABLE OCCLUSION OF THE VAS-DEFERENS [J].
GUHA, SK ;
ANAND, S ;
ANSARI, S ;
FAROOQ, A ;
SHARMA, DN .
CONTRACEPTION, 1990, 41 (03) :323-331
[9]
Guha SK, 1996, US Patent, Patent No. 54880705
[10]
Quantification by magnetic resonance spectroscopy of metabolites in seminal plasma able to differentiate different forms of azoospermia [J].
Hamamah, S ;
Seguin, F ;
Bujan, L ;
Barthelemy, C ;
Mieusset, R ;
Lansac, J .
HUMAN REPRODUCTION, 1998, 13 (01) :132-135